Avodart vs Topical Minoxidil: Head-to-Head Efficacy for Hair Loss

HealthRX.com

No head-to-head result exists for these two drugs

1 mL twice dailyLabeled men's 5% minoxidil dose, applied to the vertexSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 917 menMen in the 24-week dutasteride hair-loss trial, which also compared finasteride 1 mg and placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 0.5 mgDutasteride dose that raised hair count more than finasteride 1 mg and placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 393 menMen in the 48-week pivotal 5% minoxidil trial, compared with 2% minoxidil and placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1 mL twice dailyLabeled men's 5% minoxidil dose, applied to the vertexSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

Registered clinical studies: dutasteride and minoxidil

As of 2026-11-11, ClinicalTrials.gov lists 143 registered studies naming dutasteride and 112 naming minoxidil as an intervention. 26 and 22 of them, in that order, are phase 3.

Registered clinical studies: dutasteride and minoxidil: the figures
MeasureValue
dutasteride: registered studies143
minoxidil: registered studies112
dutasteride: recruiting now7
minoxidil: recruiting now13
dutasteride: completed108
minoxidil: completed52
dutasteride: phase 3 studies26
minoxidil: phase 3 studies22

Source: NIH National Library of Medicine, ClinicalTrials.gov, data as of Nov 11, 2026

How this was calculated

Searched the ClinicalTrials.gov intervention field for each name separately, downloaded every record and counted by status and phase.

Scope: Studies whose intervention field matches each name, any condition, all statuses; a study naming both is counted for each

Study counts show how much research is registered, not which drug works better or is safer. Older and more widely used drugs have more studies.

Download the data (CSV)

From the public record

Published papers: dutasteride and minoxidil

PubMed indexes 1,287 papers that mention dutasteride in the title or abstract and 3,063 that mention minoxidil. In 2025 the counts were 96 and 344.

Published papers: dutasteride and minoxidil: the figures
MeasureValue
dutasteride: papers, all years1,287
minoxidil: papers, all years3,063
dutasteride: papers, 2016 to 2025733
minoxidil: papers, 2016 to 20251,532
dutasteride: papers in 202596
minoxidil: papers in 2025344

Source: NIH National Library of Medicine, PubMed, data as of Nov 11, 2026

How this was calculated

Ran a PubMed title and abstract search for each name separately and recorded counts by publication year. No filtering by study type or quality.

Scope: PubMed records with each name in the title or abstract, all article types and species; a paper naming both counts for each

Paper counts show research attention, not which option works better. A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.

Download the data (CSV)

At a glance

  • FDA status / topical minoxidil 2% and 5% are over-the-counter hair regrowth products [6][9]; Avodart is approved only for benign prostatic hyperplasia [5]
  • Comparison arms used / one dutasteride hair-loss trial used finasteride and placebo [1]; another used placebo only [7]; 5% topical minoxidil was compared with 2% minoxidil, placebo and oral minoxidil [2][3][4]
  • Dutasteride evidence / 917 men, 24 weeks: 0.5 mg increased hair count more than finasteride 1 mg (P=.003) and placebo (P<.001) [1]
  • Minoxidil evidence / 393 men, 48 weeks: 5% solution beat 2% solution and placebo on nonvellus hair count [4]
  • Mechanism / dutasteride blocks both types of 5-alpha-reductase and lowered median serum DHT about 94% at 1 year [5]; the mechanism of minoxidil hair growth is not fully understood [8]
  • Dosing / the Avodart label dose for BPH is 0.5 mg once daily by mouth, and hair-loss use is off-label [5]; men's 5% solution is 1 mL twice daily to the vertex [9]
  • Sexual side effects / pooled BPH trials, months 0 to 6: impotence 4.7% on dutasteride vs 1.7% on placebo [5]
  • Combination / finasteride plus topical minoxidil improved more men than either alone at 12 months [10]

What the dutasteride trials found

A randomized 24-week trial enrolled 917 men aged 20 to 50 with androgenetic alopecia, assigned to dutasteride 0.02, 0.1 or 0.5 mg/day, finasteride 1 mg/day, or placebo [1]. The primary endpoint was hair count in a 2.54-cm diameter area, and hair count and width rose with dose [1]. Dutasteride 0.5 mg increased hair count and hair width significantly more than finasteride (P=.003 for count, P=.004 for width) and more than placebo (P<.001 for both) [1]. The authors noted the trial was limited to 24 weeks [1].

An earlier phase III trial randomized 153 men aged 18 to 49 to dutasteride 0.5 mg or placebo for 6 months [7]. Mean hair count rose 12.2/cm² on dutasteride versus 4.7/cm² on placebo (P=.0319) [7].

Dutasteride is a competitive inhibitor of both type 1 and type 2 5-alpha-reductase, the enzymes that convert testosterone to DHT; finasteride inhibits mainly type 2. It does not bind the androgen receptor [5]. On 0.5 mg daily, median serum DHT fell 85% after 1 week, 90% after 2 weeks and 94% at 1 year [5]. The terminal half-life is about 5 weeks, and serum levels can remain detectable above 0.1 ng/mL for up to 4 to 6 months after stopping [5].

None of this makes dutasteride an approved hair-loss drug. The Avodart label covers symptomatic BPH only, and hair-loss use is off-label [5]. The label dose for BPH is one 0.5 mg capsule daily, swallowed whole, with or without food [5].

What the topical minoxidil trials found

The pivotal 5% solution trial was a 48-week, double-blind study of 393 men aged 18 to 49 with androgenetic alopecia: 5% solution (n=157), 2% solution (n=158) or placebo (n=78), applied twice daily [4]. The 5% solution was superior to both 2% and placebo on nonvellus hair count, patient rating of scalp coverage and treatment benefit, and investigator rating of scalp coverage [4]. Response came earlier with 5%, and pruritus and local irritation were more frequent with 5% [4].

The parallel 48-week trial in women enrolled 381 women aged 18 to 49: 5% (n=153), 2% (n=154) or placebo (n=74) [11]. The 5% solution was superior to placebo on all three primary measures, and 2% was superior to placebo for hair count and investigator assessment [11]. The 5% group was statistically superior to the 2% group on patient assessment of treatment benefit [11]. Pruritus, irritation and hypertrichosis were more common with 5% [11].

A 16-week trial of 5% minoxidil foam in 352 men found significantly higher hair counts than placebo (P<.0001); the 52-week extension collected safety data only, with no efficacy data past 16 weeks [12].

The men's 5% solution label specifies 1 mL twice daily for the vertex in men and says it is not intended for frontal baldness or a receding hairline [9]. The women's 5% foam label directs half a capful once daily [13]. The labels say that using more or more often will not improve results, and that continued use is necessary or hair loss will begin again [9][13].

Why the numbers cannot be lined up

The dutasteride trial measured change in hair count in a 2.54-cm target circle over 24 weeks against finasteride and placebo [1]. The minoxidil solution trials measured nonvellus hair count over 48 weeks against 2% minoxidil and placebo [4][11]. Beating finasteride and beating 2% minoxidil are different results, and neither says which of the two drugs does better.

Side effects

The Avodart label reports adverse reactions from pooled 2-year BPH trials (2,167 men on dutasteride, 2,158 on placebo, mean age 66). In months 0 to 6: impotence 4.7% vs 1.7%, decreased libido 3.0% vs 1.4%, ejaculation disorders 1.4% vs 0.5%, and breast disorders 0.5% vs 0.2% [5]. The label notes these sexual reactions may persist after treatment stops and that the role of dutasteride in that persistence is unknown [5]. Those rates come from older men treated for prostate symptoms, not from men treated for hair loss.

For hair-loss doses, a meta-analysis of 15 randomized placebo-controlled trials (4,495 men) found a 1.57-fold relative risk of sexual dysfunction with 5-alpha-reductase inhibitors overall (95% CI 1.19 to 2.08). For finasteride 1 mg the relative risk was 1.66 (1.20 to 2.30); for dutasteride 0.5 mg it was 1.37 (0.81 to 2.32), which was not statistically significant, and the authors noted that dutasteride trials were few [15].

Other points from the Avodart label: it says dutasteride lowers PSA by about 50% within 3 to 6 months, that a new PSA baseline should be set at least 3 months after starting, that an isolated value in a man treated for 3 months or more should be doubled for comparison, and that any confirmed rise from the lowest on-treatment value should be evaluated [5]. The label says men on Avodart should not donate blood until at least 6 months after the last dose, and that women who are or may be pregnant should not handle the capsules [5]. It also warns of an increased risk of high-grade prostate cancer, with Gleason 8 to 10 cancer in 1.0% on Avodart versus 0.5% on placebo in the 4-year REDUCE trial [5].

In the 48-week solution trials, pruritus and local irritation were more frequent with 5% topical minoxidil than with 2% or placebo [4][11]. The men's 5% solution label describes the product as for external use only, warns that it is flammable, limits it to men, and lists chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swelling of the hands or feet, scalp irritation, and unwanted facial hair as reasons to stop use [9].

Which product is approved for hair loss

Topical minoxidil. The 2% solution was approved in 1988 and switched to over-the-counter status in 1996 [6]. Dutasteride has no hair-loss approval; its only FDA-approved use is symptomatic BPH, alone or with tamsulosin [5].

Using them together

The combination trial used finasteride, not dutasteride. In 450 Chinese men with male pattern hair loss randomized to finasteride 1 mg (n=160), 5% topical minoxidil (n=130), or both (n=160) for 12 months, improvement was reported in 80.5%, 59% and 94.1% respectively [10]. Whether dutasteride with topical minoxidil behaves the same way is not established by that trial.

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the men's 5% solution label, where is the product meant to be applied?

Question 1 of 3

Score: 0 right, 0 of 3 answered

What people on Reddit report

One Reddit thread from a man combining dutasteride with topical and oral minoxidil plus RU. Replies mostly argue about which drug did the work and how the dutasteride dose compares.

ConversationMoney976 · tressless

Dut lowers the available dht in the scalp, but RU completely prevents any dht from binding to the follicles at all. They work differently.

A commenter describes dutasteride as lowering scalp DHT, while RU is said to block DHT from binding to follicles.

Read the source discussion

Motor-Obligation-223 · tressless

They work quite differently tho. Dut just nukes dht and RU wipes any androgens left driven by testosterone in your scalp.

A commenter says dutasteride removes DHT and RU removes remaining scalp androgens, so the two act in different ways.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Frequently asked questions

Is Avodart better than topical minoxidil for hair loss?
No direct comparison exists in these trials. Dutasteride 0.5 mg increased hair count more than finasteride 1 mg and placebo over 24 weeks [1], and 5% topical minoxidil increased hair count more than 2% minoxidil and placebo over 48 weeks [4].
Is dutasteride FDA-approved for hair loss?
No. Avodart is approved only for symptomatic benign prostatic hyperplasia in men with an enlarged prostate, alone or with tamsulosin, and hair-loss use is off-label [5]. Topical minoxidil 2% and 5% are over-the-counter hair regrowth products [6][9].
Can dutasteride and minoxidil be used together?
The combination trial used finasteride, not dutasteride: 450 men took finasteride 1 mg, 5% topical minoxidil, or both for 12 months, and improvement was reported in 80.5%, 59% and 94.1% respectively [10]. That trial does not establish how dutasteride with topical minoxidil performs.
How long does each take to show results?
The men's 5% minoxidil label says results may occur at 2 months with twice-daily use and some men need at least 4 months; the women's foam label says 3 months and up to 6 months [9][13]. The dutasteride hair-count trial measured hair count at 24 weeks [1].
Does topical minoxidil cause sexual side effects?
The men's 5% solution label's stop-use list names chest pain, rapid heartbeat, faintness, dizziness, scalp irritation and unwanted facial hair [9]. Sexual side effects are documented for dutasteride, for example impotence 4.7% vs 1.7% on placebo in the first 6 months of the BPH trials [5].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is minoxidil effective in treating hair loss?

Minoxidil has trial evidence for hair regrowth, and the 5% solution performed best. In a 48-week trial of 393 men, the 5% solution beat both the 2% solution and placebo on nonvellus hair count. The 2% solution was approved in 1988 and is sold over the counter, and the mechanism of its hair growth effect is not fully understood.

Should I switch to dutasteride?

Dutasteride has not been shown to be better, so switching is not supported by these trials. There is no head-to-head result, and its only FDA-approved use is symptomatic BPH, so hair-loss use is off-label. Topical minoxidil is the only product approved for hair regrowth and is sold over the counter. Dutasteride 0.5 mg did increase hair count more than finasteride 1 mg and placebo over 24 weeks.

References

Show all 16 referencesHide references
  1. Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3.
  2. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605.
  3. Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. J Cosmet Dermatol. 2024;23(3):949-957.
  4. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85.
  5. U.S. National Library of Medicine, DailyMed. Avodart (dutasteride) soft gelatin capsules, Waylis Therapeutics prescribing information. Avodart (dutasteride) soft gelatin capsules, Waylis Therapeutics label
  6. Drugs@FDA: FDA-Approved Drugs.
  7. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-8.
  8. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
  9. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  10. Hu R, Xu F, Sheng Y, Qi S, Han Y, Miao Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28(5):303-8.
  11. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53.
  12. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74.
  13. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
  14. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 2% topical solution, Kenvue prescribing information. Women's Rogaine minoxidil 2% topical solution, Kenvue label
  15. Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99(1):12-17.
  16. Reddit participants. My current hair loss regimen - 2,5mg dut,oral min 2,5mg, topical min,ru58841 (r/tressless). Accessed 2026-11-10.
Evidence overview for compare skin hair aesthetics rx: Avodart vs Topical Minoxidil: Head-to-Head Efficacy for Hair Loss